You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)新藥LY03009在中國獲批進行臨牀試驗
格隆匯 10-27 21:33

格隆匯10月27日丨綠葉製藥(02186.HK)發佈公吿,集團中樞神經領域新藥LY03009已獲中國國家藥品監督管理局藥品審評中心批准進行臨牀試驗。LY03009用於治療帕金森病,由集團基於其長效及緩釋技術平台自主開發。

LY03009為每月給藥一次的微球注射劑,在目標給藥間隔期間能夠穩定維持血漿藥物水平。LY03009具有持續多巴胺能刺激的優點,可對運動併發症起到延緩和治療的作用,能延遲帕金森病治療中左旋多巴的引入。夜間持續有效藥物水平預期可改善夜間症狀控制和喚醒功能。每月給藥一次的目標給藥間隔可降低患者用藥頻率,簡化治療方案,提供便利,從而改善用藥依從性和臨牀療效。

除了在中國,該產品也正在澳洲開展I期臨牀試驗,並計劃在美國開展臨牀試驗。目前,全球約有1000多萬名患者飽受帕金森病的困擾;基於龐大的患者羣體和治療需求,2020年全球帕金森用藥市場規模達45.64億美元,預計2026年將以4.68%的複合年均增長率增至59.34億美元。隨着全球老齡化趨勢,董事會相信LY03009未來會有良好的市場前景,並將豐富集團的未來產品組合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account